Afleveringen
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as the launch of DDW’s latest In Focus report.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
This is the latest episode of the free DDW narrated podcast, titled “How to utilise clinical trials in drug discovery” which covers three articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW.
They are called: Medicinal cannabis: Why more clinical trials and better access is needed, What are the opportunities for decentralised clinical trials?, and Choosing the right site solution for clinical trials.
In the first article, Michael Sassano, CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area.
In the second article, Tom Brazier, Director, Decentralised Clinical Solutions, mdgroup and Stephanie Larimer, Q² Solutions discuss the opportunities for decentralised clinical trials and how common pitfalls can be avoided through communications and streamlined working.
In the third article, Independent Medical Writer Leonie Onslow explores the challenges of traditional clinical trial models and how to improve recruitment and retention.
-
Zijn er afleveringen die ontbreken?
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of cell therapy research findings revealed at EHA2024.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW.
They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack of all trades, master of…many.
In the first article, Imran Haque, VP Data Science at Recursion, describes the journey of the AI platform that predicted the efficacy of repurposed drugs for Covid-19
In the second article, Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets.
You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation to CAR-T therapies.
You can listen to the DDW podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluding this week, the headline news has all focused on breakthrough cancer research shared at the event.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology candidate, and a plant-based therapy for diarrhoea.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
This is the latest episode of the free DDW narrated podcast, titled “The future climate and landscape for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW.
They are called: Pharma’s important climate and What will the 2023 drug discovery landscape look like?
In the first article, DDW Editor Reece Armstrong comments of the impact of climate change in the drug discovery sector.
In the second article, DDW Multimedia Editor Megan Thomas observes the 2023 drug discovery landscape, speaking to industry experts and looking at the foundations of 2022 on which 2023 will lean.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.
In this episode, Megan Thomas is in conversation with Tien Lee, CEO of Aardvark Therapeutics, a San Diego-based biotech company in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut unlike GLP-1 which is systemic.
The drug targets receptors in the gut where it triggers cholecystokinin (CCK), a GI system peptide hormone responsible for stimulating the digestion of fat and protein. CCK stimulates pancreatic secretion and gallbladder contraction, regulation of gastric emptying, and sends a signal to the brain that one has had enough to eat.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the discovery of molecular doorways that could be used to help deliver drugs into the brain to treat neurological disorders, a plant-based medication which may be an effective therapy to help patients stop vaping, immune B cells which could be used to develop cancer targeting immunotherapies, and positive top-line results in Phase II/III study in schizophrenia patients.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment, this money enables scientists to produce top-quality research which will in turn result in discoveries and drugs that help tackle disease and areas of unmet need. Here are five financial success stories that made headlines this week.
You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.
In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.
Dr Worland has significant experience as a scientist and C-suite level executive/entrepreneur, and today speaks about how Selective Translation Regulator Inhibitors (STRIs) are unique to other cancer treatments, the future of the industry as well as the significance of pharma collaboration in the development process.
You can find the Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery. These include the detection of new targets for skin cancer treatment, the benefits of vitamin D for cancer prevention, an extended approval in the EU for a CAR-T myeloma therapy and the discovery of an unusual source of targeted treatments.
-
This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW.
They are called: Going paperless – the move to electronic lab notebooks, New horizon for cancer innovation, and A personal touch: the role of bioprinting in drug discovery.
In the first article, Barry Bunin, PhD, CEO of Collaborative Drug Discovery explores the rise of electronic lab notebooks and why researchers should be transitioning to digital methods of recording data.
In the second article, Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of its Therapeutics division, Hamish Ryder, to learn about the organisation’s goals.
In the third article, DDW Editor, Reece Armstrong, sits down with Brinter CEO Tomi Kalpio to learn about the company’s approach to bioprinting and how it can be used throughout drug discovery.
You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so this round-up focuses on drug discovery in oncology.
You can to The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders and alcohol use disorder, and a significant acquisition for Novo Nordisk, as well as the discovery of a new way to target dormant cancer cells.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
This is the latest episode of the free DDW narrated podcast, titled “Flow cytometry for drug discovery research” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW.
They are called: Flow cytometry technologies and cancer associated fibroblasts and Leveraging flow cytometry in drug discovery.
In the first article, Dr Amber Miller, Flow Cytometry Scientist, Fortis Life Sciences, says flow cytometry techniques can help our understanding of cancer associated fibroblasts but there is still work to be done.
In the second article, Dr Miguel A Tam, and Dr Kenta Yamamoto, BioLegend, examine the evolution, trends and best practices for smooth and efficient workflows for flow cytometry.
You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
-
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease.
You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
- Laat meer zien